Skip to main content

Advertisement

Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease

Fig. 3

Effects on inflammation and liver damage in CCL4-induced liver injury and biodistribution of pre-treated MSC. Pretreated MSC were labelled with fluorescent Qtracker 605 beads and intravenously infused in C57BL/6 mice. a Levels of MCP-1, b IP-10 and c ALT were measured in the serum 72 hours after ucMSC infusion. d Representative images of the biodistribution of pre-treated MSC in vivo 4 hours after ucMSC infusion. Yellow dots correspond with a cluster of observed MSC. e Representative image of ucMSC labelled with Qtracker 605 beads, still visible in MSC 4 hours after labelling. f Diagram showing the percentage of infused ucMSC 4 hours after administration. Figures (g) and (h) show the relative number of ucMSC in lungs and liver, respectively, calculated from the total number of detected ucMSC. Results are shown as means ± SEM (n = 4). *Indicates significant difference (p < 0.05) with respect to the CCL4 control. ALT alanine aminotransferase, CCl 4 carbon tetrachloride, IFN-γ interferon gamma, MC multiple cytokine cocktail, MCP-1 monocyte chemotactic protein-1, RA retinoic acid, Starv starvation, serum deprivation, TGFβ transforming growth factor beta, ucMSC umbilical cord-derived mesenchymal stromal cells, VitB 6 vitamin B6, pyridoxal hydrochloride

Back to article page